JP6215354B2 - 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物 - Google Patents

不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物 Download PDF

Info

Publication number
JP6215354B2
JP6215354B2 JP2015553933A JP2015553933A JP6215354B2 JP 6215354 B2 JP6215354 B2 JP 6215354B2 JP 2015553933 A JP2015553933 A JP 2015553933A JP 2015553933 A JP2015553933 A JP 2015553933A JP 6215354 B2 JP6215354 B2 JP 6215354B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
corticosteroid
sodium
dexamethasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015553933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510329A5 (enExample
JP2016510329A (ja
Inventor
マヘンドラ ジー. シャー,
マヘンドラ ジー. シャー,
Original Assignee
セムヌール ファーマシューティカルズ, インコーポレイテッド
セムヌール ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セムヌール ファーマシューティカルズ, インコーポレイテッド, セムヌール ファーマシューティカルズ, インコーポレイテッド filed Critical セムヌール ファーマシューティカルズ, インコーポレイテッド
Publication of JP2016510329A publication Critical patent/JP2016510329A/ja
Publication of JP2016510329A5 publication Critical patent/JP2016510329A5/ja
Application granted granted Critical
Publication of JP6215354B2 publication Critical patent/JP6215354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015553933A 2013-01-23 2014-01-23 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物 Active JP6215354B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361755723P 2013-01-23 2013-01-23
US61/755,723 2013-01-23
US201361776617P 2013-03-11 2013-03-11
US61/776,617 2013-03-11
PCT/US2014/012824 WO2014116876A1 (en) 2013-01-23 2014-01-23 Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid

Publications (3)

Publication Number Publication Date
JP2016510329A JP2016510329A (ja) 2016-04-07
JP2016510329A5 JP2016510329A5 (enExample) 2017-02-09
JP6215354B2 true JP6215354B2 (ja) 2017-10-18

Family

ID=50097866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553933A Active JP6215354B2 (ja) 2013-01-23 2014-01-23 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物

Country Status (13)

Country Link
US (4) US9833460B2 (enExample)
EP (1) EP2948182B1 (enExample)
JP (1) JP6215354B2 (enExample)
KR (1) KR102055937B1 (enExample)
CN (1) CN105073138B (enExample)
AU (2) AU2014209346B2 (enExample)
BR (1) BR112015017246B1 (enExample)
CA (1) CA2897467C (enExample)
IL (1) IL239791B (enExample)
MX (1) MX366654B (enExample)
NZ (1) NZ709620A (enExample)
TW (1) TWI624262B (enExample)
WO (1) WO2014116876A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ, インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方
US11857554B2 (en) * 2015-06-02 2024-01-02 Intravital Pty Ltd. Drug delivery device with pre-assembled cartridge
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
CN109152774A (zh) 2016-05-09 2019-01-04 奥尔德拉医疗公司 眼部炎性病症和疾病的组合治疗
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
JP2022511030A (ja) * 2018-12-05 2022-01-28 アルデイラ セラピューティクス, インコーポレイテッド 注射可能な製剤
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US11382863B2 (en) * 2020-03-04 2022-07-12 Somerset Therapeutics Llc Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
JP2023546445A (ja) * 2020-10-22 2023-11-02 ファイザー・インク コルチコステロイドの非経口投与のためのpegフリー水性懸濁液
JP2026502695A (ja) * 2023-01-26 2026-01-23 インシグニア・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー 変形性関節症の処置のための医薬組成物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25251A (en) 1965-07-20 1969-11-12 Merck & Co Inc Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation
US3962430A (en) 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
AU604236B2 (en) 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
FI105075B (fi) 1996-01-10 2000-06-15 Suprakort Oy Kombinaatioinjektiovalmisteen käyttö
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
JPH11279065A (ja) 1998-03-25 1999-10-12 Shiseido Co Ltd 局所投与炎症治療剤
US6921532B1 (en) * 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
US6747090B2 (en) * 2001-07-16 2004-06-08 Pharmacia Groningen Bv Compositions capable of forming hydrogels in the eye
US20040006052A1 (en) 2002-04-15 2004-01-08 Gudas Charles J. Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050186229A1 (en) 2004-02-24 2005-08-25 Emmett Clemente Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate
JP2007001926A (ja) * 2005-06-24 2007-01-11 Ltt Bio-Pharma Co Ltd 吸入・噴霧用ステロイド製剤
JP4969812B2 (ja) 2005-07-22 2012-07-04 久光製薬株式会社 ハイドロゲル組成物
US20070099882A1 (en) * 2005-10-27 2007-05-03 Gurney Harry C Methods and compositions for prolonged alleviation of articular joint pain
WO2007070547A2 (en) * 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
CN100534434C (zh) * 2006-05-15 2009-09-02 西安力邦制药有限公司 透明质酸钠地塞米松脂肪乳制剂及其应用
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US9421356B2 (en) * 2007-08-28 2016-08-23 Teikoku Pharma Usa, Inc. Transdermal methods and systems for the delivery of corticosteroid compounds
US20090143348A1 (en) 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20090143807A1 (en) 2007-12-03 2009-06-04 Vertos Medical, Inc., A Delaware Corporation Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same
WO2009129148A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Methods and compositions for treating intervertebral disc herniations
MY161021A (en) * 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US20110281834A1 (en) * 2008-11-10 2011-11-17 Friden Phillip M Pharmaceutical Formulations for Iontophoretic Delivery of a Corticosteroid
BR112012002117A2 (pt) * 2009-07-30 2019-09-24 Carbylan Biosurgery Inc composições poliméricas modificadas de ácido hialurônico e métodos relacionados.
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2459615C1 (ru) 2011-03-05 2012-08-27 Илья Александрович Марков Глазные капли для лечения болезни сухого глаза
WO2013085769A1 (en) 2011-12-06 2013-06-13 Alcon Research, Ltd. Cellulosic gel composition with improved viscosity stability
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ, インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
AU2014209346B2 (en) 2018-11-15
WO2014116876A8 (en) 2015-08-20
KR20150114505A (ko) 2015-10-12
KR102055937B1 (ko) 2019-12-13
BR112015017246A8 (pt) 2019-10-29
TWI624262B (zh) 2018-05-21
EP2948182B1 (en) 2020-09-30
AU2014209346A1 (en) 2015-07-23
CN105073138A (zh) 2015-11-18
IL239791A0 (en) 2015-08-31
US20220370476A1 (en) 2022-11-24
MX2015009455A (es) 2016-01-12
MX366654B (es) 2019-07-17
HK1218074A1 (zh) 2017-02-03
US9833460B2 (en) 2017-12-05
TW201442713A (zh) 2014-11-16
BR112015017246A2 (pt) 2017-07-11
US20180235980A1 (en) 2018-08-23
US20210052605A1 (en) 2021-02-25
AU2019200649B2 (en) 2020-02-27
BR112015017246B1 (pt) 2022-11-29
US11364251B2 (en) 2022-06-21
US10744144B2 (en) 2020-08-18
CA2897467A1 (en) 2014-07-31
US20140356434A1 (en) 2014-12-04
JP2016510329A (ja) 2016-04-07
CN105073138B (zh) 2018-06-05
WO2014116876A1 (en) 2014-07-31
NZ709620A (en) 2020-07-31
US12016867B2 (en) 2024-06-25
CA2897467C (en) 2020-09-22
AU2019200649A1 (en) 2019-02-21
IL239791B (en) 2020-11-30
EP2948182A1 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
US12016867B2 (en) Methods of treating inflammation and/or pain
US12285485B2 (en) Methods of treating pain
HK1218074B (en) Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
HK1243932B (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170920

R150 Certificate of patent or registration of utility model

Ref document number: 6215354

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250